On Mar. 23, 2020, Harvard Bioscience announced that it had launched an innovative technology – known as Accumulated Inhaled Aerosol (AIA) – for academic researchers, contract research organizations (CROs) and pharmaceutical companies involved in pre-clinical inhalation and exposure studies.

With the new Buxco AIA system, researchers are presented with real-time aerosol amounts inhaled and deposited in subjects’ lungs, a breakthrough improvement over the current delivered dose measurement. By reporting those measures against real-time respiratory endpoints using FinePointe software, researchers can observe a direct correlation between dose and lung function over time.